Cancer vaccines: A promising cancer therapy against all odds

Future Oncology

Volumn 3, Issue 3, 2007, Pages 299-306

  Silk, Ann Willman ^a   Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Active specific immunotherapy; Adjuvants; Carcinoembryonic antigen; Colorectal cancer; Dendritic cells; Immunotherapy; Melanoma; MUCI

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTINEOPLASTIC AGENT; BCG VACCINE; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELANOMA VACCINE; MUCIN 1; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROVENGE; TROVAX; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ADVANCED CANCER; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B CELL LYMPHOMA; CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER STAGING; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOLITIS; FATIGUE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE INDURATION; INJECTION SITE REACTION; INJECTION SITE ULCER; LOW DRUG DOSE; LYMPHADENOPATHY; MELANOMA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RIGOR; TUMOR GROWTH; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; VITILIGO; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS;

EID: 34347381738     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.3.299     Document Type: Review

References (50)

1. Dean M, Fojo T, Bates S: Tumor stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (2005).
2. Schulenburg A, Ulrich-Pur H, Thurnher D et al.: Neoplastic stem cells: a novel therapeutic target in clinical oncology. Cancer 107(10), 2515-2520 (2006).
3. Galon J, Costes A, Sanchez-Cabo F et al.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
4. Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y: Circulating anti-MUC 1 IgG antibodies as a favorable prognostic factor fbr pancreatic cancer. Int. J. Cancer 103, 97-100 (2003).
5. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al.: Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol. 18, 574-583 (2000).
6. Tan TT, Coussens LM: Humoral immunity, inflammation and cancer. Curr. Opin. Immunol. 19, 1-8 (2007).
7. Parish CR: Cancer immunotherapy: the past, the present and the future. Immunol. Cell Biol. 81, 106-113 (2003).
8. Klein G, Sjogren HO, Klein E, Hellstrom KE: Demonstration of resistance against methylcholanthrene induced sarcomas in the primary autochthonous host. Cancer Res. 20, 1561-1572 (1960).
9. Finn OJ: Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3, 630-641 (2003).
10. Mocellin S, Rossi CR, Lise M, Nitti D: Colorectal cancer vaccines: principles, results, and perspectives. Gastroenterology 127, 1821-1837 (2004).
11. Mosolits S, Ullenhag G, Mellstedt H: Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann. Oncol. 16, 847-862 (2005).
12. Ridgway D: The first 1000 dendritic cell vaccinees. Cancer Invest. 21, 873-886 (2003).
13. Kirkwood JM, Ibrahim JG, Sosman JA et al.: High-dose interferon Alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected. stage IIB-III melanoma: results of Intergroup Trial E1694/S9512/C509801. J. Clin. Oncol. 19, 2370-2380 (2001).
14. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT: A Phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63, 298-304 (1996).
15. Harris JE, Ryan L, Hoover HC Jr et al.: Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol. 18, 148-157 (2000).
16. Roberts TG, Goulart BH, Squitieri L et al.: Trends in the risks and benefits to patients with cancer participating in Phase 1 clinical trials. JAMA 292, 2130-2140 (2004).
17. Homma S, Sagawa Y, Ito M, Ohno T, Toda G: Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin. Exp. Immunol. 144, 41-47 (2006).
18. Mosolits S, Nilsson B, Mellstedt H: Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev. Vaccines 4, 329-350 (2005).
19. Maker AV, Phan GQ, Attia P et al.: Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II Study. Ann. Surg. Oncol. 12, 1005-1016 (2005).
20. Mukherjee P, Pathangey L, Bradley J et al.: MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine 25, 1607-1618 (2007).
21. Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J: Vaccine therapy of established tumors in the absence of autoimmunity. Clin. Cancer Res. 9(5), 1837-1849 (2003).
22. Soares MM, Mehta V, Finn OJ: Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J. Immunol. 166, 6555-6563 (2001).
23. Gong J, Chen D, Kashiwaba M et al.: Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl Acad. Sci. USA 95(11), 6279-6283 (1998).
24. Small EJ, Schellhammer PF, Higano CS et al.: Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089-3094 (2006).
25. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
26. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D: Part I: vaccines for solid tumors. Lancet Oncol. 5, 681-689 (2004).
27. Mocellin S, Mandruzzato S, Bronte V, Marincola FM: Correspondence 1: cancer vaccines: pessimism in check. Nat. Med. 10, 1278-1279 (2004).
28. Timmerman JM, Czerwinski DK, Davis TA et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99, 1517-1526 (2002).
29. Nagorsen D, Thiel E: Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin. Cancer Res. 12, 3064-3069 (2006).
30. + progenitor-derived dendritic cells. Cancer Immunol. Immunother. 55, 1209-1218 (2006).
31. Ridolfi R, Petrini M, Fiammenghi L et al.: Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. J. Transl. Med. 4, 36 (2006).
32. Harrop R, Connolly N, Redchenko I et al.: Vaccination of colorectal cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a Phase I/II trial. Clin. Cancer Res. 12, 3416-3424 (2006).
33. Keilholz U, Marius P, Scheibenbogen C: Immune monitoring of T-cell responses in cancer vaccine development. Clin. Cancer Res. 12, S2346-S2352 (2006).
34. Hoover HC Jr, Brandhorst JS, Peters LC et al.: Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a Phase III prospectively randomized trial. J. Clin. Oncol. 11, 390-399 (1993).
35. Vermorken JB, Claessen AM, van Tinteren H et al.: Active specific immunotherapy fbr stage II and stage III human colon cancer: a randomized trial. Lancet 353, 345-350 (1999).
36. Hanna MG Jr, Hoover HC Jr, Vermorken JB, Harris JE, Pinedo HM: Adjuvant active specific inummotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized Phase III trials show promise. Vaccine 19, 2576-2582 (2001).
37. Liang W, Wang H, Sun TM et al.: Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J. Gastroenterol. 9, 495-498 (2003).
38. Maxwell-Armstrong CA, Durrant LG, Buckley TJ et al.: Randomized double-blind Phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br. J. Cancer 84, 1443-4446 (2001).
39. Karanikas V, Hwang LA, Pearson J et al.: Antibody and T-cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100, 2783-2792 (1997).
40. Loveland BE, Zhao A, White S et al.: Mannan-MUC1-pulsed dendritic cell immunotherapy: a Phase I trial in patients with adenocarcinoma. Clin. Cancer Res. 12, 869-877 (2006).
41. Fong L, Hou Y, Rivas A et al.: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells fbr tumor immumotherapy. Proc. Natl Acad. Sci. USA 11, 6342-6351 (2005).
42. Marshall JL, Gulley JL, Arlen PM et al.: Phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM alone and sequentially with vaccinia-CEA (6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 23, 720-731 (2005).
43. Finn OJ: Premalignant lesions as targets for cancer vaccines. J. Exp. Med. 198(11), 1623-1626 (2003).
44. Benson AB III, Schrag D, Somerfield MR et al.: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 22, 3408-3419 (2004).
45. Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB: Adjuvant chemotherapy use for medicare beneficiaries with stage II colon cancer. J. Clin. Oncol. 20, 3999-4005 (2002).
46. Simon R: Clinical trial designs for therapeutic cancer vaccines. In: Tumor immunology and cancer vaccines. Khleif S (Ed). Kluwer Academic Publishers, MA, USA, 339-350 (2005).
47. Arlen PM, Gulley JL, Parker C et al.: A randomized Phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res. 12(4), 1260-1269 (2006).
48. Antonia SJ, Mirza N, Fricke I et al.: Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer Clin Cancer Res. 12(3 Pt 1), 878-887 (2006).
49. Zou W: Regulatory T cells, tumor immunity and immunotherapy. Nat. Rev. Immunol. 6, 295-307 (2006).
50. Lollini PL, De Giovanni C, Pannellini T, Cavallo F, Forni G, Nanni P: Cancer immunoprevention. Future Oncol. 1, 57-66 (2005).